Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluciclovine PET/CT in Pancreatic Transplants
NCT04852523Phase 1Completed
- Sponsor
- University of Utah
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in Pancreatic allograft rejection, graft pancreatitis (GP) and pancreatic graft dysfunction (PGD), sponsored by University of Utah. Primary endpoints: Measurement of Pancreatic Allograft Viability after 18F-Fluciclovine Utilization at 24 hours, Measurement of Pancreatic Allograft Visibility after 18F-Fluciclovine Utilization at 72 hours and 1 more. Started Sep 2021; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
Pancreatic allograft rejectiongraft pancreatitis (GP)pancreatic graft dysfunction (PGD)
Beyond the preview
Go deeper on NCT04852523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04852523.